Volume | 21,280,685 |
|
|||||
News | (1) | ||||||
Day High | 45.37 | Low High |
|||||
Day Low | 44.34 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Bristol Myers Squibb Co | BMY | NYSE | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
44.73 | 44.34 | 45.37 | 44.85 | 44.70 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
136,823 | 21,280,685 | $ 44.98 | $ 957,155,436 | - | 44.34 - 69.74 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:25:08 | 69 | $ 44.90 | USD |
Bristol Myers Squibb (BMY) Options Flow Summary
Bristol Myers Squibb Co Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
90.7B | 2.02B | - | 45.01B | 8.03B | 3.97 | 11.30 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Bristol Myers Squibb News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BMY Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 48.21 | 49.56 | 44.34 | 46.79 | 17,703,434 | -3.36 | -6.97% |
1 Month | 54.36 | 54.36 | 44.34 | 48.92 | 12,734,910 | -9.51 | -17.49% |
3 Months | 49.15 | 55.035 | 44.34 | 50.75 | 16,033,862 | -4.30 | -8.75% |
6 Months | 53.83 | 55.29 | 44.34 | 50.74 | 15,779,887 | -8.98 | -16.68% |
1 Year | 69.62 | 69.74 | 44.34 | 55.14 | 12,882,900 | -24.77 | -35.58% |
3 Years | 66.00 | 81.435 | 44.34 | 63.75 | 11,559,245 | -21.15 | -32.05% |
5 Years | 46.08 | 81.435 | 41.19 | 60.96 | 12,289,939 | -1.23 | -2.67% |
Bristol Myers Squibb Description
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power. |